Chicago, ILLINOIS10 Active Studies

Fanconi Anemia Clinical Trials in Chicago, ILLINOIS

Find 10 actively recruiting fanconi anemia clinical trials in Chicago, ILLINOIS. Connect with local research sites and explore new treatment options.

10
Active Trials
10
Sponsors
2,386
Enrolling

Recruiting Fanconi Anemia Studies in Chicago

RecruitingChicago, ILLINOISNCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingChicago, ILLINOISNCT07000136

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and L...

405 participants
AstraZeneca
View Study Details
RecruitingChicago, ILLINOISNCT06205225

iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure

The goal of this factorial randomized trial is to examine the independent and synergistic efficacies of two mobile health technology interventions in people with chronic heart failure. The first inter...

360 participants
University of Illinois at Chicago
View Study Details
RecruitingChicago, ILLINOISNCT06122779

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HF...

208 participants
Bristol-Myers Squibb
View Study Details
RecruitingChicago, ILLINOISNCT06616974

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the...

180 participants
Tectonic Therapeutic
View Study Details
RecruitingChicago, ILLINOISNCT04862221

TReatment for ImmUne Mediated PathopHysiology

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will de...

163 participants
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
View Study Details
RecruitingChicago, ILLINOISNCT06055439

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

135 participants
Chimeric Therapeutics
View Study Details
RecruitingChicago, ILLINOISNCT06049680

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipi...

100 participants
Fresenius Kabi
View Study Details
RecruitingChicago, ILLINOISNCT05919680

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with ...

36 participants
NorthSea Therapeutics B.V.
View Study Details
RecruitingChicago, ILLINOISNCT06270316

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people wi...

12 participants
UniQure Biopharma B.V.
View Study Details

About Fanconi Anemia Clinical Trials in Chicago

Fanconi anemia is a rare genetic disorder that affects bone marrow, reducing production of all types of blood cells and increasing cancer susceptibility. It is associated with physical abnormalities and organ defects. Treatment includes blood transfusions, growth factors, and stem cell transplant.

There are currently 10 fanconi anemia clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 2,386 participants. Research is being sponsored by Eli Lilly and Company, AstraZeneca, University of Illinois at Chicago and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Fanconi Anemia Clinical Trials in Chicago — FAQ

Are there fanconi anemia clinical trials in Chicago?

Yes, there are 10 fanconi anemia clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What fanconi anemia treatments are being tested?

The 10 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for fanconi anemia.

Data updated March 2, 2026 from ClinicalTrials.gov